The Therapeutic Significance of Mesenchymal Stem Cells in COVID-19 Acute Pulmonary Respiratory Disease

Derya Dilek Kançağı D, Ovalı E. Acibadem Labcell Cellular Therapy Laboratory, Istanbul, Turkey

Cite this article as: Dilek Kançağı D, Ovalı E. The therapeutic significance of mesenchymal stem cells in COVID-19 acute pulmonary respiratory disease. Turk Thorac J. 2022;23(5):355-363.

INTRODUCTION

In the severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) pandemic, for which we are still far from being able to say that there is an effective treatment, another important problem is that even if patients recover after intensive care, they may face significant symptoms that can last for months.1,2 In particular, this picture, called post-coronavirus disease (post-COVID) syndrome, actually has consequences as important as the disease.2 After coronavirus disease 2019 (COVID-19), this syndrome is complex, the symptoms of which are muscle weakness (53%), respiratory distress (43%), anxiety, depression, cognitive disorders, confusion, neurological symptoms including sleep disorders (40%), joint pain (27%), hair loss (22%), and cardiovascular symptoms (12%), occurs at a rate of 55% and can continue to affect patients for more than 6 months.2 Infection-induced immune reactions and mitochondrial degeneration are thought to be the main mechanisms underlying these post-COVID 19 symptoms. Therefore, post-COVID 19 treatment should not only include controlling the virus, it should also be able to control the immune reactions induced by the virus. Previous studies have shown that mesenchymal stem cells (MSCs) are effective in the treatment of many diseases.3 Likewise, studies have reported that MSCs can suppress viral infection in the treatment of SARS-CoV-2 through the secretion of specific cytokines.3 In this review, we discussed molecular, mitochondrial, and immunological events involved in the pathogenesis of novel SARS-CoV-2 as well as the clinical perspective of MSC treatment from controlled studies to improve patients’ immunological response in the post-COVID period.

CORONAVIRUS DISEASE 2019 PATHOGENESIS

Severe acute respiratory syndrome-related coronavirus-2 is a virus of the corona family and initiates the infection by its entry into the cell via the angiotensin-converting enzyme II (ACE-II) receptor. Infection begins with the synthesis of transmembrane protease serine 2 (TMPRSS2) enzyme in the host cell. The spike protein of the virus first decomposes the enzyme into 2 subunits and binds to the membrane at 2 points. Afterward, the virus is taken into the cell. Prognosis of the patient is determined by the tissue damage and the severity of the cytokine storm, which depends on the effectiveness and severity of the developing immune response.12

The most important factor that affects the level of success of the immune response is when the patients have a chronic active inflammation for another reason. Therefore, the disease progress more severely in older individuals. The underlying...
reason for this is the exaggerated immune response caused by chronic inflammation. Therefore, one of the agents widely used in the control of the disease is steroids. So why does aging go hand in hand with chronic inflammation? The most important mechanism here is thought to be mitochondrial aging or fatigue. Figure 1 summarizes this finding.

The inability of aged mitochondria to prevent the formation of the inflamasome is due to the fact that cellular stress, which increases with age, activates the nuclear factor-kB pathway. The cascade formed by the direct stimulus of the virus causes an increased presence of inflamasome (Figure 1), which is the main cause of cytokine storm in the elderly or patients with chronic inflammation. For this reason, therapeutic agents that can be ideal elements of treatment in COVID-19 should not cause primary and opportunistic infections and tissue toxicities and should also prevent mitochondrial stress and post-COVID syndrome. Unfortunately, current steroid treatments do not have this feature and cease to be an ideal agent.

FUNCTIONS AND PHARMACOKINETICS OF MESENCHYMAL STEM CELLS

Mesenchymal stem cells are shown to have regenerative effects for as long as 25 years and have been used in the clinic for their different regenerative and immunomodulatory effects for 20 years. These cells are defined as cells that can be obtained from different tissue sources, adhere to plastic, can be shown to differentiate into at least 3 mesodermal cells, and express CD45, CD34, human leukocyte antigen DR negative, CD73, CD90, CD105, and CD106. In addition, since they do not carry ACE-II and TMPRSS2 receptors, which are necessary for SARS-CoV-2 infection, and the use of these cells seems to have an advantage in the treatment of COVID-19 infection. It is now almost accepted that umbilical cord-derived MSCs are more effective than adipose and bone marrow-derived stem cells when tested for their efficacy according to their source. However, another group of researchers published a report showing that especially menstrual mesenchymal stem cells can be more effective in the treatment of COVID-19. At this point, another important issue regarding the cell source and production method is that, MSCs tend to lead to thrombosis due to the tissue factor (TF-CD142) that they carry on their surface. The use of adipose tissue-derived MSCs is controversial, especially because of their high TF transport. Therefore, researchers recommend that MSCs shall be heparinized or intramuscularly (IM) administered in order to prevent post-infusional thrombosis and the formation of pulmonary aggregates. It has even been reported that the use of the IM route can increase the duration of MSC effectiveness by 4 times, and therefore IM application will be more effective and harmless. A group of researchers also reported that extra vesicles or exosomes of MSC can be preferred over MSCs because they are independent of the risk of pulmonary MSCs and are also effective.

MESENCHYMYAL STEM CELLS CAN EXERT THEIR REGENERATIVE AND IMMUNOMODULATORY EFFECTS BY THE FOLLOWING MECHANISMS

Regenerative Mechanisms of Action

While MSCs stimulate healing in damaged tissue through mitochrondria transfer, mRNA, miRNA transfers, and cytokines such as keratinocyte growth factor, hepatocyte growth factor, vascular endothelial growth factor, and insulin-like growth factor 1, can reduce apoptosis in tissue with the activation of antiapoptotic effect (B-cell lymphoma 2). In fact, the transformation of M1 macrophages into M2 macrophages, which starts with the phagocytosis of MSC or MSC extravesicles, is a part of the immune modulation process and is almost one of the main mechanisms of the regenerative process. Moreover, this reaction is especially responsible for the formation of the regenerative cytokine profile. It has been reported that it can prevent fibrosis in the post-COVID-19 period.

IMMUNOREGULATORY MECHANISMS OF ACTION

While MSCs decrease the functions of T and B lymphocytes, they can increase apoptosis in these cells. In addition, they suppress tissue-specific immune responses by increasing T-regulatory (Treg), B-regulatory, and DC-regulatory levels. However, another group of researchers published a report showing that especially menstrual mesenchymal stem cells can be more effective in the treatment of COVID-19. At this point, another important issue regarding the cell source and production method is that, MSCs tend to lead to thrombosis due to the tissue factor (TF-CD142) that they carry on their surface. The use of adipose tissue-derived MSCs is controversial, especially because of their high TF transport. Therefore, researchers recommend that MSCs shall be heparinized or intramuscularly (IM) administered in order to prevent post-infusional thrombosis and the formation of pulmonary aggregates. It has even been reported that the use of the IM route can increase the duration of MSC effectiveness by 4 times, and therefore IM application will be more effective and harmless. A group of researchers also reported that extra vesicles or exosomes of MSC can be preferred over MSCs because they are independent of the risk of pulmonary MSCs and are also effective.

MESENCHYMYAL STEM CELLS PHARMACOKINETICS

In a study conducted in the acute respiratory distress syndrome (ARDS) model, intravenous (IV) and endobronchial (EB) MSCs were administered to normal and ARDS-induced mice, and kinetic analyzes were evaluated. Kinetic analyzes for intravenous and endobronchial administration of MSCs show that, in case of lung damage, 80% of MSC remains in the lung tissue after intravenous administration. However, in this study, it is reported that in the normal mice...
group, a significant part of MSC administered intravenously is distributed throughout the body 5 hours after administration, and the majority of these dispersed cells are localized to the brain, liver, and kidney. Another finding in this study shows that MSCs given intravenously can be more localized in areas with aeration disorder. There was no difference between the effect of IV or EB administration on improving lung functions. In addition, studies comparing IV and IM applications reported that the effect of IM application may be longer and greater than IV application, 26,27 it has been shown that IV administration in hypercoagulant conditions can cause microemboli in the lung. 25 When all these are considered together it seems possible to say that EB and/or IM administration in COVID-19-related ARDS may be safer and even more effective.

CLINICAL DATA

When the ClinicalTrials.gov site is examined, it is seen that more than 84 studies have been conducted on ARDS and

Figure 1. The mechanism of exaggerated but uncontrolled antiviral immunity observed in critically ill patients caused by mitochondrial aging/dysfunctioning (modified from Ayala DJMF et al. 2020) ROS, reactive oxygen species; mtDNA, mitochondrial DNA; miRNA, microRNA; NF-kβ, nuclear factor kβ; TNFα, tumor necrosis factor alpha; IL-6, interleukin 6; IFN-γ, interferon gamma.

Figure 2. Mesenchymal stem cells can control the reaction at every step in coronavirus disease 2019 infection progressing with cytokine storm.
| Study                     | Center  | Reference | Study design                                                                 | Result                                                                                                           |
|--------------------------|---------|-----------|-------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Lanzoni G, et al., 2021  | USA     | 37        | A double-blind, phase 1/2a, randomized, controlled trial                      | No serious adverse events (SAEs)                                                                                  |
|                          |         |           | UC-MSC treatment (n = 12); control group (n = 12)                            | Decreased level of inflammatory cytokines in UC-MSC-treated patients (P < .05).                                 |
|                          |         |           | UC-MSC treatment group received 2 intravenous infusions (at day 0 and 3):    | Significantly improved patient survival (91% vs. 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). |
|                          |         |           | 100 ± 20 x 10⁶ UC-MSCs; controls: 2 infusions of vehicle solution.          |                                                                                                                 |
|                          |         |           | • No serious adverse events (SAEs)                                           |                                                                                                                 |
|                          |         |           | • Decreased level of inflammatory cytokines in UC-MSC-treated patients (P < .05). |                                                                                                                 |
|                          |         |           | • Significantly improved patient survival (91% vs. 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). |                                                                                                                 |
| Shu L, et al. 2020       | China   | 38        | A single-center open-label, individually randomized, standard treatment-controlled trial | The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, |
|                          |         |           | Standard treatment group (n = 29); the standard treatment plus hUC-MSC     | 4 patients in the control group had critical condition with invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. |
|                          |         |           | infusion group (n = 12)                                                     |                                                                                                                 |
|                          |         |           | 2 x 10⁶ cells/kg hUC-MSC                                                    | In the hUC-MSC treatment group, the time to clinical improvement was decreased compared to the control group. |
|                          |         |           | • The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, | Improvement of clinical symptoms with hUC-MSC treatment: Weakness and fatigue, shortness of breath, and low oxygen saturation |
|                          |         |           | • 4 patients in the control group had critical condition with invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. | IL-6 levels were decreased significantly; |
|                          |         |           | • In the hUC-MSC treatment group, the time to clinical improvement was decreased compared to the control group. | 2.5 times higher survival rate in the UC-MSCs group than that in the control group (P = .047; 10 patients vs 4 patients). |
|                          |         |           | • Improvement of clinical symptoms with hUC-MSC treatment: Weakness and fatigue, shortness of breath, and low oxygen saturation | In patients with comorbidities, UC-MSC administration increased the survival rate by 4.5 times compared with controls. |
|                          |         |           | • IL-6 levels were decreased significantly;                                 | No adverse events were reported.                                                                 |
|                          |         |           | • 2.5 times higher survival rate in the UC-MSCs group than that in the control group (P = .047; 10 patients vs 4 patients). | Decreased CRP and interleukin 6 in the recovered patients (P = .023) after UC-MSC infusion. |
| Dilogo IH, et al. 2021   | Indonesia | 39   | A double-blind, multicentered, randomized controlled trial.                 | In control group, levels of plasma sTNFR2, TNFα, and TNFβ were not significantly different between days 0 and 6. |
|                          |         |           | • n = 40,                                                                    | Significant decrease in TNFα and TNFβ levels (P = .005 and P = .002, respectively) in UC-MSC treatment group at day 6. |
|                          |         |           | • All patients received standard therapy                                     | Significantly higher levels of sTNFR2 (26.609 ± 846 pg/ml vs. 23.111 ± 760 pg/ml, P = .021) and significantly lower levels of TNFα (319 ± 40 vs. 950 ± 226 pg/ml, P = .048) and TNFβ (810 ± 126 vs. 2.944± 735 pg/mL, P = .032) in UC-MSC treatment group. |
|                          |         |           | • 20 patients received an intravenous infusion of 1 x 10⁹/kg body weight UC-MSCs and 20 patients received 100 mL 0.9% saline solution as the control group. | Improved whole-lung lesion volume with a difference of −10.8% (P = .030) after MSC administration on day 10. |
|                          |         |           | • No difference in adverse events                                           | MSC therapy reduced the ratio of solid component lesion volume.                                                 |
|                          |         |           | • In control group, levels of plasma sTNFR2, TNFα, and TNFβ were not significantly different between days 0 and 6. | Normal CT images at month 12: 17.9% (10/56) of patients in the MSC group; none in the placebo group (P = .013). |
|                          |         |           | • Significant decrease in TNFα and TNFβ levels (P = .005 and P = .002, respectively) in UC-MSC treatment group at day 6. | No difference in adverse events                                                                                   |
|                          |         |           | • Significantly higher levels of sTNFR2 (26.609 ± 846 pg/ml vs. 23.111 ± 760 pg/ml, P = .021) and significantly lower levels of TNFα (319 ± 40 vs. 950 ± 226 pg/ml, P = .048) and TNFβ (810 ± 126 vs. 2.944± 735 pg/mL, P = .032) in UC-MSC treatment group. |                                                                                                                 |
| Shi L, et al. 2021       | China   | 41        | A prospective, randomized, double-blind, placebo-controlled, longitudinal, cohort study trial. | Improved whole-lung lesion volume with a difference of −10.8% (P = .030) after MSC administration on day 10. |
|                          |         |           | 100 patients enrolled in phase 2 trial were prospectively followed up for 1 year. | MSC therapy reduced the ratio of solid component lesion volume.                                             |
|                          |         |           | UC-MSCs (n = 65) or placebo (n = 35) in addition to standard care.          | Normal CT images at month 12: 17.9% (10/56) of patients in the MSC group; none in the placebo group (P = .013). |
|                          |         |           | • Improved whole-lung lesion volume with a difference of −10.8% (P = .030) after MSC administration on day 10. | No difference in adverse events                                                                                   |
| Study                  | Center     | Reference | Study design                                                                 | Result                                                                                     |
|-----------------------|------------|-----------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Saleh M, et al. 2021  | Iran       | 42        | A phase 1 clinical trial • Five patients with severe COVID-19 were treated with Wharton’s jelly-derived mesenchymal stem cells (150 × 10⁶ cells per injection). These patients were subject to 3 intravenous injections 3 days apart. | Increased level of IL-10 and SDF-1 MSC therapy, but decreased level of VEGF, TGF-β, IFN-γ, IL-6, and TNFα. No SAEs. |
| Xu X, et al. 2021     | China      | 24        | A multicenter, open-label, nonrandomized, parallel-controlled exploratory trial. • An allogeneic, menstrual blood-derived MSC therapy and concomitant medications (3 infusions totaling 9 × 10⁶ MSCs, 1 infusion every other day, n = 26); only concomitant medications (control group; n = 18). | Significantly lower mortality rate in the MSC group (7.69% died in the experimental group vs 33.33% in the control group; P = .048). Improved chest imaging results in the first month after MSC infusion. Similar incidence of most AEs between the groups. |
| Sengupta V, et al. 2020 | USA       | 43        | A prospective nonblinded, nonrandomized open-label cohort study • Cohort A (n = 2), Cohort B (n = 21), Cohort C (n = 4) • A single 15 mL intravenous dose of ExoFlo, a bmMSC-derived exosome agent | No adverse events observed within 72 hours of ExoFlo administration. A survival rate: 83%; patients recovered: 17 of 24 (71%), patients remained critically ill though stable: 3 of 24 (13%), and patients expired for reasons unrelated to the treatment: 4 of 24 (16%) |
| Meng F, et al. 2020   | China      | 44        | A parallel assigned controlled, non-randomized, phase 1 clinical trial • 18 hospitalized patients with COVID-19 (n = 9 for each group) • Three cycles of intravenous infusion of UC-MSCs (3 × 10⁷ cells per infusion) on days 0, 3, and 6. | No SAEs related to UC-MSCs infusion. Need of mechanical ventilation in 1 patient in the treatment group when compared with 4 patients in the control group. Decreased serum IL-6 in the UC-MSCs-treatment group. Decreased trend in the levels of cytokines within 14 days: interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), monocyte chemoattractant protein 1 (MCP-1), interferon-inducible cytokine IP-10 (IP-10), IL-22, interleukin 1 receptor type 1 (IL-1RA), IL18, IL-8, and macrophage inflammatory protein 1-alpha (MIP-1) |
| Ercealen N, et al. 2021 | Turkey | 45        | n = 210 • Every patient received UC-MSCs (1-2 × 10⁶ per kilogram) on average 6.4 days after positive severe acute respiratory syndrome-related coronavirus-2 diagnosis. | Rate of good clinical progress/discharged from intensive care unit: 52.5% (n = 52) patients (out of 99 critically severe intubated patients). 86 (77.5%) of 111 severe unintubated patients discharged from intensive care unit. 47 (47.5%) patients and unintubated 25 (22.5%) patients pass away. Significantly higher survival rate was analyzed in patients infused UC-MSCs before intubation (odds ratio = 1.475, 95% CI = 1.193-1.824 P < .001). No adverse events in patients received UC-MSC infusion |
COVID-19 infection, and 13 of them were performed with MSC exosomes (3 IV, 10 of them inhaled exosome application). As of today, it is seen that there are 9 studies whose results have been published in the control of COVID-19 ARDS. Of these, 5 were randomized placebo-controlled including 2 phase I/II and 1 phase II studies, 2 were non-randomized controlled, 1 was non-randomized without control and 4 were case studies. Two were uncontrolled studies including 1 phase I study and 1 non-randomized cohort study (Table 1). The common point of these studies is that the use of MSCs or exosomes is a safe practice.24,37-48

### SUMMARY ANALYSIS OF PUBLISHED RANDOMIZED CONTROLLED STUDIES IN COVID-19

When only published controlled studies were examined, control (n = 12) and MSC (n = 12; 100 million/IV single dose) groups were compared in a phase I/II randomized controlled study conducted in the USA.37 In this study, investigators reported that cytokine storm could be easily controlled in the MSC group. The most important result of this study is that the survival rate in the MSC group was 91%, while it was reported as 42% in the control group.

| Study       | Center    | Reference | Study design                           | Result                                                                 |
|-------------|-----------|-----------|----------------------------------------|----------------------------------------------------------------------|
| Hashemian SMR, et al. 2021 | Iran 46   | Case study | The patients received 3 intravenous infusions (200 × 10^6 cells) every other day; human umbilical cord MSCs (UC-MSCs; n = 6) or placental MSCs (PL-MSCs; n = 5). | No SAEs                                                              |
|             |           |           |                                        | Significant reductions in 6 patients in serum levels of tumor necrosis factor-alpha (TNF-α; P < .01), IL-8 (P < .05).          |
|             |           |           |                                        | Decreased IL-6 levels in 5 (P = .06) patients and interferon gamma (IFN-γ) levels in 4 (P = .14) patients. Four patients with the signs of multi-organ failure or sepsis died in 5-19 days (average: 10 days) after the first MSC infusion. |
|             |           |           |                                        | Remarkable signs of recovery seen in lung CT scans.                   |
| Zengin R, et al. 2020 | Turkey 47 | A case report of a COVID-19 patient progressed to severe disease with intubation and intensive care need. An investigational MSC infusion was applied in intensive care unit, via intratracheal and intravenous routes (0.7 × 10^6 cells/kg intravenous, 0.3 × 10^6 cells/kg intratracheal with 4 units of heparin). A second dose of MSC therapy (0.7 × 10^6 cells/kg intravenous, 0.3 × 10^6 cells/kg intratracheal routes with 4 unites of heparin) was given 5 days after the first dose. | No adverse events                                                     |
|             |           |           |                                        | Improved clinical signs                                               |
|             |           |           |                                        | An invasive ventilation for the next 5 days continued following the second dose. |
|             |           |           |                                        | On day 19 of hospitalization, lung chest x-ray showed slight regression in the ground-glass imaged infiltration in the middle right lung periphery, and significant remission in the low-density infiltrations in the lower right lung and lateral left lung. |
| Yalcin K, et al. 2020 | Turkey 48 | Case series | 7 patients diagnosed COVID-19 Totally 1 × 10^6 UC-MSC/kg was administered for once in each patient by combined routes, intravenous (7 × 10^5 MSC/kg) and intratracheal (3 × 10^5 UC-MSC/kg through intubation tube) subsequently. At the time of MSC administration, all 7 patients were taking mechanical ventilation. | Significant reduction in the level of C-reactive protein of all patients [(before MSC therapy; mean: 84.8 mg/L (2.4-272 mg/L); after MSC administration, mean: 6.5 mg/L (0.3-25.3 mg/L)]. |
|             |           |           |                                        | Decreased procalcitonin level for 6 of 7 patients, increasing lymphocyte count for 5 of 7 patients and pulmonary functions PaO₂/FiO₂. |
|             |           |           |                                        | Improved Positive End-Expiratory Pressure level for 5 of 7 patients within 7 days after MSC infusion. |
|             |           |           |                                        | After MSC infusion, 4 of 7 patients were weaned from mechanical ventilation. |
Another double-blind, multicentered, randomized controlled trial (n = 40) evaluated the UC-MSCs (1 x 10^6/kg body weight) vs control group (0.9% saline solution). This study reported that the survival rate in the UC-MSCs group was 2.5 times higher than that in the control group (P = .047; 10 patients versus 4 patients. In addition, UC-MSC administration increased the survival rate by 4.5 times compared with controls in patients with comorbidities.39

In a publication from China,31 66 patients who received low-dose 40 million/IV single-dose MSCs were compared with 35 control patients. In this study, nonsignificant positive differences were observed in biochemical parameters, survival, and length of stay, but the reduction in lung lesions resulted in a statistically significant difference in the MSC group.

In the study by X et al34 with menstrual mesenchymal stem cells, 3 million/kg MSC was given to 26 patients every other day; while the placebo group was followed up with standard care. In this study, investigators reported that cytokine storm could be controlled with MSC, and this was reflected in the clinic, resulting in a significant decrease in mortality, which was 33% in the placebo arm, and 7.7% in the MSC group 10.

In another placebo-controlled study conducted by Shu L et al.38 12 patients who received 2 million cells/kg of single-dose MSCs originating from the human umbilical cord were compared with 29 patients who received a placebo. In this study, while C-reactive protein and interleukin-6 levels were significantly decreased in the MSC group, improvement in lymphocyte count and oxygenation levels were also detected in the MSC group. While the median recovery time was 7 days in the MSC group, it was significantly longer in the placebo group at 14 days. The 28-day mortality was 0% in the MSC group and 10.34% in the placebo group. However, these data are not statistically significant.

Contrary to these results, Meng F et al.34 compared patients in whom they infused low-dose 30 million/IV dose of cord blood-derived MSCs 3 times sequentially with 9 control patients. However, although they found improvement in cytokine levels and respiratory functions in the MSC group, this was not statistically significant.

Apart from these controlled studies, MSCs have been reported to control cytokine storm in case–control series report (Table 1). In the study conducted by our group on this subject, 80 million MSCs originating from the umbilical cord were administered intravenously. 20 million MSCs were administered via endobronchial way, with an interval of 4 days, and it was reported that stem cells could significantly control the cytokine storm in patients and positively affect respiratory parameters.47,48

Considering all these existing studies, the most important shortcoming of these studies is that their analysis includes the acute and subacute periods. It seems that none of these studies analyzed the post-COVID period. Especially in these patients, oxidative stress, mitochondrial aging, and the presence of inflammasome continue after the disease and may cause post-COVID syndrome. In this respect, the use of MSCs during post-COVID treatment may have a positive effect. However, clinical evidence of theoretical knowledge has not yet emerged, as studies with MSC so far have not analyzed the effects of this treatment in the post-COVID period. Therefore, the effect of MSC use on post-COVID syndrome should be studied in particular. It should even be discussed in the treatment of post-COVID syndrome.49

CONCLUSION

In the treatment of COVID-19 infection, MSCs, which can interfere with the pathogenesis of the disease at many points, may be effective in accordance with pre-clinical data in clinical practice data. The most important point that can be said about this subject for now is that MSCs are a reliable treatment agent in the treatment of COVID-19. However, new, large and controlled studies to be planned in terms of the effectiveness of MSCs need to confirm the available data. In addition, the effects of MSCs used for treatment on COVID and post-COVID syndrome are promising and needs to be further studied. The following 2 questions must also be answered in these studies: First, what are the effects of MSCs used in the treatment of COVID on the post-COVID that will develop over a long period of time? Second, will there be efficacy of MSCs after post-COVID develops? Studies are needed to answer these questions.

REFERENCES

1. Çelik D, Köse Ş. Erkşinerlde COVID-19: Klinik Bulgular. Tep- ecik Eğit Araşt Hast Derg. 2020;30(Ek sayı):43-8.
2. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. [CrossRef]
3. Gao G, Fan C, Li W, et al. Mesenchymal stem cells: ideal seeds for treating diseases. Hum Cell. 2021;34(6):1585-1600. [CrossRef]
4. Baykal B. Mesenchymal stem cells for the treatment of various diseases. J Stem Cell Res Med. 2016;1(2). [CrossRef]
5. Regmi S, Pathak S, Kim JO, Yong CS, Jeong JH. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives. Eur J Cell Biol. 2019;98(5-8):151041. [CrossRef]
6. Wang LT, Liu KJ, Sytwu HK, Yen ML, Yen BL. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Trans Med. 2021;10(9):1288-1303. [CrossRef]
7. Daulerova M, Hafsan H, Mahhengam N, Zekiy AO, Ahmadi M, Siahmoursi H. Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: a review study. Clin Immunol. 2021;226:108712. [CrossRef]
8. Monguuo-Tortajada M, Bayes-Genis A, Rosell A, Roura S. Are mesenchymal stem cells and extracellular vesicles valuable to halt the COVID-19 inflammatory cascade? Current
9. Vishnu priya M, Navend kumar M, Manjima K, et al. Post-COVID pulmonary fibrosis: therapeutic efficacy using with mesenchymal stem cells—how the lung heals. 

10. Haberle H, Magunia H, Lang P, et al. Mesenchymal stem cell therapy for severe COVID-19 ARDS. 

11. Chatterjee SK, Saha S, Munoz MNM. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. 

12. Moreno Fernández-Ayalá DMM, Navas P, López-Lluch G. Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. 

13. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. 

14. McGuire PJ. Mitochondrial dysfunction and the aging immune system. 

15. Sandhir R, Halder A, Sunkaria A. Mitochondria as a centrally positioned hub in the innate immune response. 

16. Missi ri violating the weak immune antibodies? 

17. Jamai kha M, Asa di Y, A zangou-Khyav y M, et al. MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak. 

18. Pagliaro P. Is macrophage heterogeneity important in determining COVID-19 lethality? 

19. Bektas A, Shur man SH, Francesc hi C, et al. Public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short-and long-term inflammaging? 

20. Jamalkha M, Asa di Y, Azangou-Khyav y M, et al. MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak. 

21. Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y. Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, prolifera tion and differentiation. 

22. Bár cia RN, Sant ros JM, Filipe M, et al. What makes umbilical cord tissue–derived mesenchymal stromal cells superior immunomodulators when compared to bone marrow derived mesenchymal stromal cells? 

23. Alcyocay-Miranda F, Cuenca J, Martin A, Con tres la, Figue res F, Khour y M. Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis. 

24. Xu X, Jiang W, Chen L, et al. Evaluation of the safety and efficacy of using human menstrual blood–derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: an exploratory clinical trial. 

25. Moll G, Drzenie k N, K amhiheh-Milz J, Geiss ler S, Vo lk HD, Reineke P. MSC therapies for COVID-19: importance of patient coagulopathy, thrombophrophaxis, cell product quality and mode of delivery for treatment safety and efficacy. 

26. Braid LR, Wood CA, Wiese DM, Ford BN. Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes. 

27. Caplan I, Olson SD, Kumar A, et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. 

28. Qazi TH, Duda GN, Ort MJ, Perka C, Geissler S, Winkler T. Cell therapy to improve regeneration of skeletal muscle injuries. 

29. Ask enase PW. COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: do the exosomes in convalescent plasma antagonize the weak immune antibodies? 

30. Gorman E, Millar J, McCauley D, O’Kane C. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. 

31. Sadeghi S, Soudi S, Shah iee A, Hashemi SM. Mesenchymal stem cell therapies for COVID-19: current status and mechanism of action. 

32. Dabrowska S, Andrzejewska A, Janowski M, et al. Immunomodulatory and regenerative effects of mesenchymal stem cells and extracellular vesicles: therapeutic outlook for inflammatory and degenerative diseases. 

33. Miteva K, Papp ritz K, Sosnowski M, et al. Mesenchymal stromal cells inhibit NLRP3 inflammasome activation in a model of coxsackievirus B3-induced inflammatory cardiomyopathy. 

34. Cardenes N, Aranda-Valderrama P, Carney JP, et al. Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model. 

35. Kavianpour M, Saleh M, Verdi J. The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm. 

36. Oh JY, Ko JH, Lee HJ, et al. Mesenchymal stem/stromal cells inhibit the NLRP3 inflammasome by decreasing mitochondrial reactive oxygen species. 

37. Lanzoni G, Linetsk y E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. 

38. Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. 

39. Di ligo IJ, Adi nian gish D, Su g iarto A, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial. 

40. Kouroupi dis D, Lanzoni G, Linetsk y E, et al. Umbilical cord–derived mesenchymal stem cells regulate TFN and soluble TNF receptor 2 (sTNFR2) in COVID-19 ARDS patients. 

41. Shi L, Huang H, Lu X, et al. Effect of human umbilical cord–derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. 

42. Saleh M, Vaezi AA, A liannejad R, et al. Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial. 

43. Sungupta V, Sungupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells for ARDS for COVID-19: importance of patient coagulopathy, thrombophrophaxis, cell product quality and mode of delivery for treatment safety and efficacy. 

44. Front Immunol. 2020;11:1091.
as treatment for severe COVID-19. *Stem Cells Dev.* 2020;29(12):747-754. [CrossRef]

44. Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase I clinical trial. *Signal Transduct Target Ther.* 2020;5(1):172. [CrossRef]

45. Ercelen NO, Pekkoc-Uyanik KC, Alpaydin N, Gulay GR, Simsek M. Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey. *Stem Cell Rev Rep.* 2021;17(5):1917-1925. [CrossRef]

46. Hashemian SR, Aliannejad R, Zarrabi M, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. *Stem Cell Res Ther.* 2021;12(1):91. [CrossRef]

47. Zengin R, Beyaz O, Koc ES, et al. Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report. *Stem Cell Investig.* 2020;7:17. [CrossRef]

48. Yalcin K, Hemsinlioglu C, Zengin R, et al. Mesenchymal stromal cell therapy for critically ill patients With COVID-19. *JMIR Prepr.* 2020;20206.

49. Lage SL, Amaral EP, Hilligan KL, et al. Persistent oxidative stress and inflammasome activation in CD14<sup>high</sup>CD16<sup>−</sup> monocytes from COVID-19 patients. *Front Immunol.* 2021;12:799558. [CrossRef]